FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Safety and efficacy of vilaprisan in Japanese women with fibroids: The Phase 3 ASTEROID 8 trial. PMID 41059527 · Womens Health (Lond) · 2025 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Safety & efficacy of thulium laser endoscopic en bloc resection versus conventional trans urethral resection of bladder tumors, for treatment of non muscle invasive bladder tumors: A prospective randomized trial. PMID 41050386 · Arab J Urol · 2025 Eligibility criteria not met: study lacks a drug-containing intervention (compares surgical techniques) and lacks a time-to-event primary/key secondary efficacy endpoint (recurrence rate is a categorical outcome at 12 months, not a survival/recurring event analyzed with KM/HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial. PMID 41050349 · Front Surg · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial. PMID 41049580 · Ther Adv Med Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial. PMID 41042207 · Cancer Control · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA). PMID 41040645 · Wellcome Open Res · 2025 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Bowel Preparation for Colonoscopy: The Patient Point of View. PMID 41021426 · Dig Dis · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials. PMID 41018097 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparison of Postoperative Analgesic Effects of Intravenous versus Perineural Dexamethasone Injection Combined with Ropivacaine in Thoracoscopy-Guided Thoracic Paravertebral Block for Thoracoscopic Radical Lung Cancer Resection: A Prospective Randomized Controlled Trial. PMID 41017807 · Drug Des Devel Ther · 2025 Study is a randomized, prospective, human oncology trial, but it lacks a drug-containing intervention (the intervention is anesthetic technique and analgesic adjuvant) and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials. PMID 41000392 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Case report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma. PMID 40989691 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. PMID 40980453 · Neurooncol Adv · 2025 This publication is a methodological study that applies and validates clinical benefit assessment scales (ESMO-MCBS, ASCO, Neuro-MCBS) to a collection of existing neuro-oncology studies. It is not an original result report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint. The abstract describes the development and testing of a scoring tool, not the presentation of trial-specific efficacy data. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. PMID 40971945 · PLoS One · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| DEHyART trial: Study protocol for phase 2 randomised controlled study assessing the role of dose escalation using [18F] fluoromisonidazole positron emission tomography/computed tomography in head and neck cancers. PMID 40949474 · Ecancermedicalscience · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect analysis of percutaneous catheter drainage combined with radiofrequency ablation in the treatment of mixed thyroid nodules. PMID 40937415 · Front Endocrinol (Lausanne) · 2025 The study is a randomized trial on benign thyroid nodules (non-malignant), uses a non-drug intervention (radiofrequency ablation and catheter drainage), and reports outcomes such as tumor size, treatment duration, pain, hoarseness, and recurrence counts without Kaplan-Meier or HR analysis, failing to meet eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Photodynamic Therapy and 5-Fluorouracil Cream versus Surgical Excision in Treatment of Bowen's Disease: A Trial-Based Economic Evaluation. PMID 40934140 · Dermatology · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors. PMID 40924700 · PLoS One · 2025 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Generic Intravenous Amisulpride (QLG2069) for the Prevention of Postoperative Nausea and Vomiting in Adults: A Phase III, Multicenter, Randomized, Placebo-Controlled Study. PMID 40923005 · Drug Des Devel Ther · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. PMID 40918097 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Strategy-based cognitive rehabilitation for childhood brain tumour: Protocol for an acceptability and feasibility trial of the Fatigue, Learning, and Memory Enrichment (FLaME) intervention. PMID 40917737 · NIHR Open Res · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya: Study Protocol for a Phase II Clinical Trial. PMID 40907021 · Cancer Control · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluation of a digital health platform for preventing stroke in the Australian community: Study protocol for a randomized controlled trial - Love Your Brain. PMID 40906720 · PLoS One · 2025 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease. PMID 40904419 · Alzheimers Dement (N Y) · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [Future directions in the management of warm autoimmune hemolytic anemia]. PMID 40903253 · Rinsho Ketsueki · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013). PMID 40901464 · Front Immunol · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Study protocol for a randomized controlled clinical trial of a multifaceted cognitive training program using video games in childhood cancer survivors. PMID 40892751 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of radiofrequency and exercise-based rehabilitation on symptoms associated with pelvic floor dysfunction in breast cancer patients: A study protocol. PMID 40880350 · PLoS One · 2025 The record is a study protocol, not a formal result report. It lacks reported efficacy data. Furthermore, it does not meet core eligibility criteria: the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, the interventions are non-drug only (radiofrequency and pelvic floor muscle training), and the primary endpoints are not time-to-event efficacy measures (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis. PMID 40875656 · PLoS One · 2025 The record describes a randomized trial in rheumatoid arthritis, not oncology. While it is a human randomized trial with drug interventions and reports survival analysis for remission, the disease is non-oncologic and the endpoint (time to remission in RA) is not an oncology time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bibliometric analysis of biologic treatments for chronic rhinosinusitis. PMID 40861204 · Front Med (Lausanne) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The anti-inflammatory and antioxidant effects of astaxanthin as an adjunctive therapy in community-acquired pneumonia: a randomized controlled trial. PMID 40852606 · Front Pharmacol · 2025 The study is not an oncology trial; it is a randomized controlled trial for community-acquired pneumonia, a non-malignant condition. The primary endpoint is inflammatory markers, not a time-to-event efficacy outcome. The intervention is a supplement (astaxanthin), not a cancer drug. Therefore, it is excluded on multiple grounds. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact on outcomes of ultra hypofractionation or hypofractionation regimens and proton or Xrays therapy in a phase III randomized controlled trial MC1635. PMID 40842574 · Front Oncol · 2025 The record is a Phase III randomized controlled trial in oncology, but it lacks a specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and the intervention appears to be radiation therapy (hypofractionation/proton vs. X-ray) without a drug component, making it ineligible. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial. PMID 40823083 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The efficacy of early progressive resistance exercise in the postoperative management of pancreaticoduodenectomy for pancreatic cancer: a randomized controlled trial. PMID 40822270 · Front Surg · 2025 The study is a randomized controlled trial in pancreatic cancer surgery evaluating an exercise intervention, but it lacks a drug intervention and does not report any time-to-event efficacy endpoints like OS, PFS, DFS, etc. It focuses on recovery metrics and quality of life. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans. PMID 40801059 · South Afr J HIV Med · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial. PMID 40800123 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Controlled Trial Comparative Study in Powered and Manual Stapler in Low Anterior Resection of Rectal Cancer. PMID 40798889 · Asian J Endosc Surg · 2025 The study is a randomized controlled trial in rectal cancer patients comparing two surgical staplers, not a drug intervention. It does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR; the primary outcome is anastomotic leakage (a complication), with logistic regression analysis. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355). PMID 40791599 · Front Immunol · 2025 The study is a retrospective real-world analysis and does not meet the requirement for a Phase III/IIIb or Phase II/III randomized trial. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients. PMID 40777124 · Front Oncol · 2025 The record describes a subgroup analysis from a Phase III randomized trial in NSCLC evaluating neoadjuvant chemoimmunotherapy cycles. While it is oncologic, human, randomized, Phase III, and drug-intervening, the primary endpoint reported is pathological complete response (pCR), a binary pathological outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The analysis is explicitly a subgroup analysis based on ctDNA-MRD status. Therefore, it does not meet the inclusion criteria for a time-to-event primary/key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of peripherally-restricted κ-opioid receptor agonist-HSK21542 for postoperative analgesia in patients undergoing laparoscopic abdominal surgery: a randomized, placebo-controlled phase 2 trial. PMID 40776930 · Front Med (Lausanne) · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparison of endoscopic and endoscope-assisted microscopic transsphenoidal surgery for pituitary adenoma resection: a prospective randomized study. PMID 40766292 · Front Endocrinol (Lausanne) · 2025 Study compares surgical techniques for pituitary adenoma, lacks drug intervention, and does not report time-to-event efficacy endpoints like OS or PFS with Kaplan-Meier or HR. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of control arms in oncology randomised trials in Brazil: a cross-sectional study. PMID 40765840 · BMJ Oncol · 2025 This is a cross-sectional methodological study analyzing control arms of trials, not an original report of a single trial's efficacy results. It does not present time-to-event efficacy data (OS, PFS, etc.) from a specific trial. The drug intervention criterion cannot be established from this secondary analysis. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acceptability and implementation potential of a health literacy intervention to increase colorectal cancer screening in deprived areas: A qualitative study of patients and general practitioners participating in a cluster randomized controlled trial. PMID 40763131 · PLoS One · 2025 The record is a qualitative study of a health literacy intervention for colorectal cancer screening. While it is from a randomized controlled trial (cluster RCT), it does not meet key eligibility criteria: it lacks a drug-containing intervention, no time-to-event efficacy endpoint is reported, and the phase is not established as Phase III/IIIb or Phase II/III. The study reports patient and provider acceptability, not efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer. PMID 40761936 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Brucea javanica oil emulsion plus supportive care for refractory advanced colorectal cancer: a pilot RCT protocol. PMID 40761400 · Front Pharmacol · 2025 The record is a protocol for a future trial, not an original result report of a completed randomized trial with a drug intervention and time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exploratory unsupervised machine learning of angiogenesis biomarkers in a phase II advanced cervical cancer trial of radiochemotherapy with or without neoadjuvant chemotherapy. PMID 40743651 · Clinics (Sao Paulo) · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Non-Randomized Controlled Trial Comparing Response of Rectal Cancer Chemoradiation with and without Low-Dose Aspirin. PMID 40740570 · Med J Islam Repub Iran · 2025 The study is a non-randomized controlled trial (explicitly stated in title and methods), which excludes it from being a randomized trial. The phase is not specified, and there is no indication it is Phase III/IIIb. The primary endpoint is pathological complete response (pCR), which is not a time-to-event efficacy endpoint. No time-to-event data (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier curves, or hazard ratios are reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated radiotherapy for head and neck squamous cell carcinoma. PMID 40737737 · Cancer Radiother · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Remote High-Intensity Aerobic Interval Training on Quality of Life and Physical Health in Breast Cancer Survivors: Two Years Follow-Up. PMID 40735810 · Integr Cancer Ther · 2025 Study is an oncology, human, randomized controlled trial reporting original results. However, it does not meet key eligibility criteria: the intervention is non-drug-only (exercise), there is no time-to-event efficacy endpoint (OS, PFS, etc.), the phase is not explicitly stated as III/IIIb, and the primary endpoint is quality of life/physical health (not time-to-event efficacy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a Care Plan Based on the Multi-Theory Model in Reducing Fear of Disease Progression and Improving Quality of Life in Breast Cancer Patients: A Randomized Controlled Trial. PMID 40735051 · Breast Cancer (Dove Med Press) · 2025 The study is a randomized controlled trial in breast cancer patients receiving adjuvant chemotherapy, but it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR results. The primary outcomes are psychological and quality-of-life measures (fear of progression, quality of life, self-management efficacy). The phase is not specified in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pancreatoduodenectomy versus total pancreatectomy and simultaneous intraportal islet autotransplantation for periampullary cancer at high-risk of postoperative pancreatic fistula (XANDTX-trial): Protocol of a randomized controlled pilot trial. PMID 40720532 · PLoS One · 2025 Excluded because it is a protocol (no results), lacks a drug-containing intervention, and does not establish a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |